Hunan Yongren Medical Innovation 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   1 Trial   0 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TGFβ targeting CAR-T cells / Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine
ZZCART-003, NCT03198546: GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

Recruiting
1
30
RoW
GPC3 and/or TGFβ targeting CAR-T cells
Second Affiliated Hospital of Guangzhou Medical University, Hunan Zhaotai Yongren Medical Innovation Co. Ltd., Guangdong Zhaotai InVivo Biomedicine Co. Ltd., First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer
08/29
08/36
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells / Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine
NCT03198052: GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

Recruiting
1
30
RoW
CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR, Administration of CAR-T cells through vein or interventional technique.
Second Affiliated Hospital of Guangzhou Medical University, Hunan Zhaotai Yongren Medical Innovation Co. Ltd., Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
Lung Cancer, Cancer, Immunotherapy, CAR-T Cell
08/26
08/36

Download Options